NAP1L5 in acute myeloid leukemia: a prognostic biomarker and potential therapeutic target
NAP1L5 emerges as a promising prognostic biomarker and therapeutic target in AML, offering potential for improved patient outcomes and precision treatment strategies.
Authors
- Yuanyuan Tan (ORCID: https://orcid.org/0009-0006-7550-5769)
- Lili Zhou (ORCID: https://orcid.org/0000-0002-0910-8689)
- Tingting Zhang (ORCID: https://orcid.org/0000-0002-4390-1939)
- Yuqing Du (ORCID: https://orcid.org/0000-0002-9147-656X)
- Yan Zhou (ORCID: https://orcid.org/0000-0001-9402-1109)
- Zhibin Xie (ORCID: https://orcid.org/0009-0004-5981-687X)
- Huan Wu (ORCID: https://orcid.org/0000-0002-8689-0379)
- Jian Ge (ORCID: https://orcid.org/0000-0002-7063-3933)
- Meng Wang (ORCID: https://orcid.org/0009-0005-4676-7682)
Institutions
- Bengbu Medical College (CN)
- Anhui Medical University (CN)
- First Affiliated Hospital of Anhui Medical University (CN)
- First Affiliated Hospital of Bengbu Medical College (CN)
Publication Details
- Journal
- Frontiers in Oncology
- Published
- 2025-07-25
- DOI
- https://doi.org/10.3389/fonc.2025.1617564
- Citations
- 1
- Primary Topic
- RNA modifications and cancer
- Type
- article
- Field-Weighted Citation Impact
- 0.81